Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2024.1369562 Oncology Correction Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions Generali Daniele 1 2 * Berardi Rossana 3 Caruso Michele 4 Cazzaniga Marina 5 6 Garrone Ornella 7 Minchella Ida 8 Paris Ida 9 Pinto Carmine 10 De Placido Sabino 11 1 Breast Cancer Unit, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy 2 Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy 3 Medical Oncology, Azienda Ospedaliera Universitaria (AOU) delle Marche, University Politecnica delle Marche, Ancona, Italy 4 Humanitas Istituto Clinico Catanese, Breast Centre Humanitas Catania, Catania, Italy 5 School of Medicine and Surgery University of Milano Bicocca, Milan, Italy 6 Phase 1 Research Unit, Azienda Socio Sanitaria Territoriale (ASST) Monza, Monza, Italy 7 Medical Oncology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy 8 Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy 9 Department of Woman and Child Health and Public Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy 10 Medical Oncology Unit, Comprehensive Cancer Centre, Azienda Unità Sanitaria Locale - Istituto di Ricerca e Cura a Carattere Scientifico (AUSL-IRCCS) di Reggio Emilia, Reggio Emilia, Italy 11 Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: Daniele Generali, dgenerali@units.it

23 01 2024 2024 14 1369562 12 01 2024 15 01 2024 Copyright © 2024 Generali, Berardi, Caruso, Cazzaniga, Garrone, Minchella, Paris, Pinto and De Placido 2024 Generali, Berardi, Caruso, Cazzaniga, Garrone, Minchella, Paris, Pinto and De Placido

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Aromatase inhibitors: the journey from the state of the art to clinical open questions by Generali D, Berardi R, Caruso M, Cazzaniga M, Garrone O, Minchella I, Paris I, Pinto C and De Placido S (2023) Front. Oncol. 13:1249160. doi: 10.3389/fonc.2023.1249160 aromatase inhibitors bone loss cardiotoxicity drug adherence breast cancer section-in-acceptance Breast Cancer

In the published article, there was an error in affiliation 8. Instead of “Division of Early Drug Development, European Institute of Oncology, Milan, Italy”, it should be “Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.